Project Grant R01MH134828

Award Date 8/7/24
Completion Date 4/30/29
Dollars Obligated $2.7M
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
This federal Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $784,642 to the New York Genome Center, Inc. (NYGC) to leverage electronic health records and genomic data to develop predictive models and subtypes for clinical outcomes in psychosis-related disorders. The key objectives are to: Build machine learning-based models to forecast treatment response, illness severity, medical comorbidities, and...
This Project Grant award of $162,000.00 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) supports research to investigate the transcriptional diversity of the human mediodorsal thalamus and its role in the pathogenesis of schizophrenia and bipolar disorder. The key objectives are to: 1) Use single-nucleus RNA-sequencing to define transcriptional signatures of diverse cell types in the human mediodorsal thalamus and explore...
This Project Grant award of $3,093,740 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) supports the "A Schizophrenia Extension Study for the NKI Rockland Sample II Project: An Open Resource of Multimodal Brain, Physiology & Behavior from a Community Lifespan Sample". The project leverages the ongoing NKI-Rockland Sample II (NKI-RSII) study's extensive neuroimaging, neurophysiological, and behavioral data to create an...
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $1,491,482 to Brigham & Women's Hospital Inc. to investigate mechanism-based biomarkers of schizophrenia using neuroimaging techniques. The research aims to characterize the relationship between neuroimaging findings, blood biomarkers, and cognitive deficits in schizophrenia, with the goal of developing clinically-feasible analytical...
This $735,932 federal Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) supports research to elucidate the mechanisms underlying positive symptoms of schizophrenia, such as auditory hallucinations. The award, with a performance period from April 2025 to January 2030, will be conducted by St. Jude Children's Research Hospital Inc. in Memphis, Tennessee. The key objectives are to characterize the disruption of...
This $1,854,632 Project Grant awarded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will support research to examine the link between mitochondrial dysfunction and synaptic deficits in schizophrenia. The project, led by The Children's Hospital of Philadelphia (CHOP), aims to study mitochondrial biogenesis, mitophagy, and glutamatergic synaptic release in induced pluripotent stem cell (iPSC)-derived neurons from individuals with...
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $2,415,243 to The Broad Institute, Inc. to develop a scalable, cloud-based framework for multi-modal mapping across single neuron omics, morphology, and electrophysiology. The framework aims to enable integrative, data-driven characterization of brain cell types, leveraging federated Brain Initiative resources and community engagement....
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $811,404 to The Trustees of Columbia University in the City of New York to conduct research on the neural circuit mechanisms underlying anticipatory anhedonia in schizophrenia. The key objectives of this 5-year research project are to: 1) Establish the relationship between anticipatory value computation and anhedonia traits through...
This $449,228 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) supports the development of an integrated system for long-term electrophysiological profiling of human brain organoids. The key products and services to be delivered include: A biological assay chamber that supports chronic electrophysiology while maintaining the health of brain organoids. High-fidelity, 3D neural probes for chronic, extracellular...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $443,671 to The Lieber Institute for Brain Development (LIBD) to investigate the molecular, cellular and circuit-level mechanisms underlying sustained attention deficits observed in neuropsychiatric disorders. The research leverages genetic and circuit-specific tools to dissect the role of the locus coeruleus-anterior cingulate cortex circuit and the...

This federal Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $2,694,945 to the Lieber Institute for Brain Development (LIBD) to conduct research on understanding the cellular and circuit mechanisms underlying schizophrenia.

The key products and services to be delivered under this award include: 1) Replicating and expanding on prior findings from 2D cell culture models of patient-derived induced pluripotent stem cell (iPSC) lines, relating cellular phenotypes to clinical and cognitive symptoms of schizophrenia; and 2) Utilizing 3D cortical organoid models to confirm prior phenotypes and discover novel molecular and cellular alterations in early cortical development associated with schizophrenia risk. This multi-modal approach, including electrophysiology, RNA sequencing, proteomics, and metabolomics, aims to identify cellular mechanisms linked to the etiology, pathophysiology, and symptomatology of schizophrenia, with the goal of enabling precision psychiatry and identifying potential therapeutic targets.

Generated 6/24/25, 5:40 AM